When ASX Blue Chips Bleed: Here Are 5 Of The Largest 1 Day Crashes!

A >40% fall in a day is something ASX investors would expect from a speculative microcap, not from blue chips. But it does happen, and most recently with Tuas (ASX: TUA) earlier this week. The stock shed over 60% in a single session, was one of the most dramatic single-day destructions of shareholder value in recent ASX history.

Yet it was not unprecedented. The ASX has periodically produced blue-chip or near-blue-chip one-day implosions, events that tend to follow a recognisable anatomy: an overstretched valuation, a single catalyst that invalidates the core investment thesis, and an institutional exodus that amplifies the move well beyond what fundamentals alone would justify. The lessons are both cautionary and, for disciplined long-term investors, occasionally opportunistic.

5 Of The Largest One Day Crashes Amongst ASX Blue Chips

1. Cochlear: The ‘Never Disappoint’ Stock That Did

The Cochlear (ASX: COH) implosion on 22 April 2026 was, in many respects, a more textbook example of the large-cap one-day crash. The company had long occupied a privileged position in the ASX healthcare universe: a dominant global hearing implant manufacturer with high barriers to entry, recurring revenue characteristics, and a premium valuation that investors consistently forgave because the earnings delivery had been so reliable.

That aura of reliability evaporated in a single session. Management cut FY26 underlying profit guidance from A$435–460m down to A$290–330m, a reduction of approximately 30% at the midpoint. The reasons were unusually broad-based: softer US demand, weaker consumer sentiment in key markets, delayed surgical procedures in Europe, Middle East disruptions, currency headwinds, and a slower-than-anticipated rollout of the Nucleus Nexa platform.

The stock fell roughly 40% in the session, with shares briefly trading near A$101 against a prior close near A$168. That made it the company’s largest one-day decline on record. The scale of the reaction reflected a dual compression: earnings expectations and the valuation multiple collapsed simultaneously. A stock priced as a high-quality compounder cannot sustain a premium earnings multiple once the ‘never disappoint’ narrative breaks. Cochlear’s case illustrates why the highest-rated stocks carry the most asymmetric downside when guidance misses.

2. Magellan: Trust Evaporation in Waves

Magellan (ASX: MFG) never suffered a one-day ‘Tuas-style’ collapse, but its experience between 2021 and 2022 is arguably more instructive precisely because the destruction was cumulative. And there were two ‘bad days’, especially in early 2022 – first when it lost the St James mandate and the second was when Hamish Douglass departed. Quarterly update after quarterly update that showed an FUM decline gradually compounded up over time. From highs near A$75 per share in early 2020, the stock eventually fell more than 85% at the trough, driven by a series of severe one-day drawdowns that compounded into a structural re-rating.

Unlike leveraged blowups such as Babcock & Brown (which we’ll get to shortly), Magellan was a trust evaporation story. The business had enormous operating leverage in reverse. Once performance weakened and outflows began, the structural fragility became apparent. It is worth noting the parallels with Platinum Asset Management, which followed a broadly similar trajectory, and with AMP, where repeated confidence shocks produced a sequence of heavy one-day declines that collectively removed most of the stock’s value.

3. Slater & Gordon (ASX:SGH)

Slater & Gordon (ASX: SGH) had been one of the ASX’s most ambitious growth experiments: an Australian plaintiff law firm that had gone public, scaled aggressively, and then attempted an audacious expansion into the UK market via the acquisition of Quindell’s professional services division in 2015.

The stock had traded above A$8 per share and commanded a market capitalisation exceeding A$2bn at its peak. The collapse, when it came, was severe. During the 2015 crisis period, shares fell more than 50% in individual sessions as accounting concerns surrounding the Quindell acquisition emerged and investor confidence collapsed. The UK business proved far more problematic than management had presented, and questions about revenue recognition and the true value of the acquired claims book effectively destroyed the equity story. Slater & Gordon ultimately entered administration, its shares reduced to a fraction of their peak value.

The Slater & Gordon experience is a canonical example of the ‘failed transformational acquisition’ archetype, one that recurs across the cases here with telling regularity. Management teams frequently underestimate integration risk, regulatory complexity, and the quality of assets they are purchasing, particularly in cross-border transactions where information asymmetry is highest. The market, once it grasps the scale of the miscalculation, tends to reprice with brutal efficiency.

4. Babcock & Brown

The Babcock & Brown collapse during the 2008 Global Financial Crisis stands as the most extreme leverage-driven example in this cohort. It wasn’t quite the impact of Lehman but probably the closest Australia had. At its peak, Babcock & Brown commanded a market capitalisation exceeding A$8bn, having built a complex infrastructure and structured finance empire that was heavily reliant on debt markets remaining open and accommodating.

When the GFC struck, those conditions reversed violently. The company suffered multiple single-session declines of 25–50% during 2008 as debt fears, covenant concerns, and repeated write-downs triggered capitulation selling. Reuters reported one such session in June 2008 where shares fell approximately 25% in a day, with the stock down more than 50% over two sessions. The related entity Babcock & Brown Power suffered an intraday collapse of more than 50% in August 2008 following a profit downgrade tied to Alinta asset write-downs.

Babcock & Brown ultimately failed, entering administration in 2009. Its collapse was not a governance surprise in the Slater & Gordon sense, nor a regulatory shock in the Tuas sense: it was the entirely predictable consequence of excessive leverage meeting a systemic liquidity crisis. The lesson is a simple one: debt amplifies both upside and downside, and when the downside arrives at scale, equity holders absorb losses that vastly exceed what the underlying business deterioration would otherwise imply.

5. AMP (ASX:AMP)

AMP (ASX: AMP) delivered one of the more jarring results-day selloffs in recent memory when it released its FY25 results in mid-February 2026. The stock crashed over 26% on the day, its largest single-session decline since 2003 when it fell 36%. AMP reported a 20.8% lift in underlying NPAT, a 9% increase in total AUM, and an 11.3% decline in statutory NPAT, with the result falling well below market expectations across the board.

The AMP case is instructive because the numbers, on their surface, were not catastrophic. The underlying profit was actually higher. What the market was repricing was confidence: in management continuity (the CEO transition had already unsettled investors earlier in the year), in the earnings quality given the statutory drag from legacy legal settlements, and in the credibility of the post-divestment business model following the sale of its advice and insurance divisions in 2024. That combination left the stock down 27% for the year-to-date at the close of that session alone.

The AMP experience is perhaps the purest illustration of how expectation gaps, rather than absolute earnings outcomes, drive these events. A 20% profit increase that still misses consensus is punished more severely than modest earnings that meet it. The market does not price what happened; it prices what it thought would happen.